Rosuvastatin

Generic Name: Rosuvastatin

Brand Names: Crestor, Ezallor, Roszet

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈FN_₃O_₆S

CAS Number: 287714-41-4

Unique Ingredient Identifier: 413KH5ZJ73

Background: Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...

Indication: The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...

Associated Conditions: Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia

Associated Therapies: Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases

Clinical Trials

Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)

Not Applicable

Recruiting

Conditions: Acute Aortic Syndrome
Aortopathy

Interventions: Drug: Rosuvastatin 10mg

First Posted Date: 2021-01-07

Last Posted Date: 2024-12-13

Lead Sponsor: Nanjing Medical University

Target Recruit Count: 300

Registration Number: NCT04699279

Locations: 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳
The first affiliated hospital of nanjing medical university, Nanjing, Jiangsu, China
🇨🇳
Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

and more 2 locations

A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Rosuvastatin
Drug: SPC ezetimibe/rosuvastatin
Drug: Rosuvastatin active capsule
Drug: Placebo

First Posted Date: 2020-12-16

Last Posted Date: 2022-06-23

Lead Sponsor: Sanofi

Target Recruit Count: 305

Registration Number: NCT04669041

Locations: 🇨🇳
Investigational Site Number :1560006, Hohhot, China
🇨🇳
Investigational Site Number :1560045, Changchun, China
🇨🇳
Investigational Site Number :1560067, Changchun, China

and more 37 locations

Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: PF-06882961
Drug: Rosuvastatin
Drug: Midazolam

First Posted Date: 2020-11-09

Last Posted Date: 2023-12-01

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT04621227

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Atorvastatin
Drug: Pravastatin
Drug: Rosuvastatin
Drug: Filgotinib

First Posted Date: 2020-10-29

Last Posted Date: 2022-06-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 27

Registration Number: NCT04608344

Locations: 🇺🇸
Prism Research, LLC, Saint Paul, Minnesota, United States

Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)

Phase 1

Active, not recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Rosuvastatin (Inhibitor arm)
Drug: Rosuvastatin
Drug: Eltrombopag

First Posted Date: 2020-09-09

Last Posted Date: 2024-01-23

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 20

Registration Number: NCT04542382

Locations: 🇺🇸
Ucsf Ctsi Crc, San Francisco, California, United States

Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Rosuvastatin
Drug: Branebrutinib

First Posted Date: 2020-08-17

Last Posted Date: 2022-03-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 22

Registration Number: NCT04515628

Locations: 🇺🇸
ICON (LPRA) - Salt Lake, Salt Lake City, Utah, United States

Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct

Phase 2

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Rifampicin
Drug: Rosuvastatin 10mg
Drug: Isoniazid
Drug: Pyrazinamide
Drug: Ethambutol

First Posted Date: 2020-08-07

Last Posted Date: 2020-08-07

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 154

Registration Number: NCT04504851

Locations: 🇺🇬
Joint Clinical Research Centre, Kampala, Uganda
🇻🇳
Vietnam Military Medical University, Hanoi, Vietnam
🇵🇭
Tropical Disease Foundation, Makati City, Philippines

and more 3 locations